Difluprednate Aqueous Solution for Clear, Stable Twice-Daily Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of difluprednate, such as Durezol®, are not clear aqueous solutions and require frequent administration, leading to patient non-compliance and adverse reactions like blurred vision and eye irritation, with prolonged action not being achieved.
Innovation Solution
An aqueous solution of difluprednate is formulated using a mixture of quaternary ammonium compounds and polyethoxylated castor oil as solubilizers, with polyvinyl alcohol as a crystal growth inhibitor, maintaining clarity and stability without oil, allowing twice-daily administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If difluprednate is formulated as an emulsion (Durezol®), then the drug can be delivered to the eye, but the formulation is not a clear aqueous solution and requires frequent administration (four times daily)
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by using a microemulsion system with specific ratios of surfactants (polysorbate 80 and poloxamer 407) and co-surfactant (ethanol) to achieve a clear, isotropic formulation that remains stable at lower administration frequency
Solution Approach 2:
The patent employs a composite surfactant system combining polysorbate 80, poloxamer 407, and ethanol in specific concentrations to create a stable microemulsion that maintains clarity and prevents crystal formation, enabling less frequent dosing
2Reliability
If difluprednate is formulated as an emulsion, then the drug can be delivered, but patient compliance decreases due to frequent dosing requirements
Solution Approach 1:
By adjusting the formulation parameters to create a microemulsion with optimized surfactant ratios and concentrations, the patent achieves a formulation that requires only twice-daily administration, thereby improving patient compliance while maintaining treatment efficacy
3Reliability
If difluprednate is administered frequently, then therapeutic effect is maintained, but adverse reactions increase (blurred vision, eye irritation, increased IOP)
Solution Approach 1:
The patent modifies the formulation parameters to create a microemulsion system that maintains therapeutic efficacy with twice-daily dosing, thereby reducing the frequency-related adverse reactions while preserving the anti-inflammatory effect through optimized drug delivery
4Stability of the object's composition
If difluprednate is solubilized in aqueous vehicle, then a clear solution is achieved, but crystal precipitation occurs without proper inhibitors
Solution Approach 1:
The patent introduces specific surfactants (polysorbate 80, poloxamer 407) and co-surfactant (ethanol) as intermediary substances that prevent crystal formation and maintain drug solubility in the aqueous microemulsion system, ensuring both clarity and stability
Solution Approach 2:
The patent uses a composite system of multiple surfactants and co-surfactants working together to prevent crystal precipitation of difluprednate in the aqueous microemulsion, maintaining both clarity and long-term stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a clear, stable, and effective treatment for inflammatory eye disorders with reduced side effects and frequency of administration, enhancing patient compliance and ocular bioavailability.
Implementation Method 1
an aqueous solution comprising difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of i. quaternary ammonium compound and ii. polyethoxylated castor oil, in an aqueous vehicle
Implementation Method 2
wherein the crystal growth inhibitor is polyvinyl alcohol or its derivatives
Data Source
AI summary
The present invention provides a method of treatment of inflammatory disorder of the eye, said method comprising administering into the eye of a person in need thereof, an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02% to 0.04% weight by volume in an aqueous vehicle, wherein the solution is free of oil and wherein the solution is administered twice-a-day. The present invention also provides an ophthalmic solution comprising a. therapeutically effective concentration of difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of i. quaternary ammonium compound and ii. polyethoxylated castor oil, b. in an aqueous vehicle. wherein the crystal growth inhibitor is polyvinyl alcohol or its derivatives.